Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-06-30FDA Approved: RYLAZE — Original Application (Jazz Pharmaceuticals, Inc.)
FDA approved RYLAZE (ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN) in an original application. It is indicated for the treatment of …
-
CLINICAL_TRIALS trial_result · 2021-06-30Clinical Trial Update: High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia [NA]
Clinical trial update on high-throughput drug sensitivity assay and genomics-guided treatment for relapsed or refractory acute leukemia; stu…
-
FDA approval · 2021-06-29FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories, enabling continued or expanded marketing under a…
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy [Phase 2]
Phase 2 trial update on intravenous Erwinaze for patients with allergy to frontline asparaginase therapy in acute lymphoblastic leukemia or …
-
FDA approval · 2021-06-14FDA Approved: TREXALL — Supplemental Application (Teva Women's Health, Inc.)
The FDA approved a supplemental application for TREXALL (methotrexate) filed by Teva Women's Health, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Unrelated Umbilical Cord Blood (UBC)Transplantation [NA]
Clinical trial update for unrelated umbilical cord blood transplantation; the study is completed with results posted in 2021.
-
FDA approval · 2021-05-19FDA Approved: CLOFARABINE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Clofarabine (generic) by Mylan Institutional LLC under ANDA208860.
-
CLINICAL_TRIALS trial_result · 2021-05-13Clinical Trial Update: A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase I-II open-label trial of TL32711 in acute myeloid leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia; study terminat…
-
CLINICAL_TRIALS trial_result · 2021-05-03Clinical Trial Update: Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 2]
Phase 2 trial evaluating combination chemotherapy and Ofatumumab in adults with acute lymphoblastic leukemia or lymphoblastic lymphoma compl…
-
CLINICAL_TRIALS trial_result · 2021-05-03Clinical Trial Update: Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial evaluating blinatumomab in adults with high-risk B-cell precursor acute lymphoblastic leukemia is ongoing (active, no…
-
CLINICAL_TRIALS withdrawal · 2021-04-27Clinical Trial Update: Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT [Phase 3]
Phase 3 randomized trial evaluating standard of care with or without atorvastatin for prevention of graft-versus-host disease in matched unr…
-
FDA approval · 2021-04-14FDA Approved: CLOFARABINE — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application from Gland Pharma Limited for Clofarabine under an ANDA, authorizing its use as a generic product. T…
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 study assessing the combination of chemotherapy with inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia, inc…
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Busulfan and Cyclophosphamide Followed By ALLO BMT [NA]
Clinical trial update for busulfan and cyclophosphamide followed by allogeneic stem cell transplant in acute leukemias; study is terminated …
-
CLINICAL_TRIALS trial_result · 2021-04-12Clinical Trial Update: Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial evaluating Inotuzumab Ozogamicin for relapsed or refractory CD22-positive acute lymphoblastic leukemia has been terminated wit…
-
FDA approval · 2021-03-25FDA Approved: IMATINIB — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for imatinib from Dr. Reddy's Laboratories, supporting an update to the drug's labeling under the AN…
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial update for an anti-CD19 CAR-T cell therapy in B cell malignancies has completed recruiting.
-
FDA approval · 2021-03-11FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for BLINCYTO (blinatumomab) from Amgen, resulting in updated labeling and an expanded indication…
-
CLINICAL_TRIALS trial_result · 2021-02-26Clinical Trial Update: Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial evaluating treosulfan, fludarabine phosphate, and total-body irradiation as conditioning before donor stem cell transplant in …
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia [Phase 2]
Phase 2 clinical trial evaluating haploidentical stem cell transplantation for children with therapy-resistant leukemia (ALL and AML) has be…
-
CLINICAL_TRIALS trial_result · 2021-02-04Clinical Trial Update: Vaccinating Children After Chemotherapy [Phase 4]
Phase 4 trial update on vaccinating children after chemotherapy for acute lymphoblastic leukemia; results posted.
-
FDA approval · 2021-01-29FDA Approved: MERCAPTOPURINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for mercaptopurine by Mylan Pharmaceuticals, updating the regulatory status for the marketed product…
-
FDA approval · 2021-01-25FDA Approved: MERCAPTOPURINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for mercaptopurine submitted by Hikma Pharmaceuticals USA Inc., indicating changes to the product's …
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-T cells targeting CD19 and CD22 for relapsed or refractory acute lymphoblastic leukemia.
-
FDA approval · 2021-01-14FDA Approved: VINCRISTINE SULFATE — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application filed by Hospira for vincristine sulfate, a generic vincristine product.